Terns Pharmaceuticals, Inc. Property, Plant, Equpment (Net)

Property, Plant, Equpment (Net) of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Property, Plant, Equpment (Net) growth rates and interactive chart. Property, plant, and equipment (aslo called PP&E) are a company's physical or tangible long-term assets that typically have a life of more than one year. Examples of PP&E include buildings, machinery, land, office equipment, furniture, and vehicles.


Highlights and Quick Summary

  • Property, Plant, Equpment (Net) for the quarter ending March 31, 2022 was $1.11 Million (a 6.12% increase compared to previous quarter)
  • Year-over-year quarterly Property, Plant, Equpment (Net) increased by 15.75%
  • Annual Property, Plant, Equpment (Net) for 2021 was $1.05 Million (a -10.98% decrease from previous year)
  • Annual Property, Plant, Equpment (Net) for 2020 was $1.18 Million (a 22.27% increase from previous year)
  • Annual Property, Plant, Equpment (Net) for 2019 was $961 Thousand (a 268.2% increase from previous year)
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Property, Plant, Equpment (Net) of Terns Pharmaceuticals, Inc.

Most recent Property, Plant, Equpment (Net)of TERN including historical data for past 10 years.

Interactive Chart of Property, Plant, Equpment (Net) of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Property, Plant, Equpment (Net) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $1.11
2021 $1.05 $0.93 $0.96 $1.03 $1.05
2020 $1.18 $1.18
2019 $1.23 $0.96
2018 $0.26

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.